Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectinmediated protein wave of hemostasis

Journal of Biomedical Research

Volumn 29, Issue 6, 2015, Pages 437-444

  Hou, Yan ^a,b   Carrim, Naadiya ^a,c,d   Wang, Yiming ^a,c,d   Gallant, Reid C ^a,c   Marshall, Alexandra ^a   Ni, Heyu ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Jilin Provincial Center for Disease Prevention and Control   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Fibrinogen; Fibronectin; Integrin IIb 3; Platelets; Thrombosis and hemostasis

Indexed keywords

FIBRINOGEN; FIBRONECTIN; PROTEIN; THROMBIN;

ATHEROSCLEROSIS; BLOOD CLOTTING; CELL GRANULE; HEMOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PLATELET GRANULE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RELEASE REACTION; THROMBOGENICITY; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 84957440989     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.29.20150121     Document Type: Review

References (109)

1. Osler W. An account of certain organisms occurring in the liquor sanguinis[J]. Proc R Soc Lond, 1874;391-398.
2. Bizzozero G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione[J]. L'Osservatore, 1881;785-787.
3. Bizzozero G. Uber einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und Blutgrinnung[ J]. Virchows Archiv, 1882;261-332.
4. Wright J. The origin and nature of blood platelets[J]. Boston Med Surg J, 1906;643-645.
5. Ruggeri ZM. Platelets in atherothrombosis[J]. Nat Med, 2002, (8):1227-1234.
6. Ni H, Freedman J. Platelets in hemostasis and thrombosis:role of integrins and their ligands[J]. Transfus Apher Sci, 2003, (28):257-264.
7. Wang Y, Andrews M, Yang Y, et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms[J]. Cardiovasc Hematol Disord Drug Targets, 2012, (12):126-132.
8. Coller BS. Historical perspective and future directions in platelet research[J]. J Thromb Haemost, 2011, (9 Suppl 1):374-395.
9. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'[J]. Nat Rev Drug Discov, 2003;(2), 775-789.
10. Gachet C. Antiplatelet drugs: which targets for which treatments?[J]. J Thromb Haemost, 2015, (13):S313-322.
11. Mackman N. Triggers, targets and treatments for thrombosis[J]. Nature, 2008, (451):914-918.
12. Michelson AD. Platelets, 2013;(3rd edition).
13. Schmaier AA, Stalker TJ, Runge JJ, et al. Occlusive thrombi arise in mammals but not birds in response to arterial injury: evolutionary insight into human cardiovascular disease[J]. Blood, 2011, (118):3661-3669.
14. Machlus KR, Italiano JE, Jr. The incredible journey: From megakaryocyte development to platelet formation[J]. J Cell Biol, 2013, (201):785-796.
15. Italiano JE, Jr., Lecine P, Shivdasani RA, et al. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes[J]. J Cell Biol, 1999, (147):1299-1312.
16. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow[J]. Science, 2007, (317):1767-1770.
17. Thon JN, Montalvo A, Patel-Hett S, et al. Cytoskeletal mechanics of proplatelet maturation and platelet release[J]. J Cell Biol, 2010, (191):861-874.
18. Fuentes R, Wang Y, Hirsch J, et al. Infusion of mature megakaryocytes into mice yields functional platelets[J]. J Clin Invest, 2010, (120):3917-3922.
19. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocytegenerated platelets in mice: a cautionary tale[J]. Blood, 2015, (125):3627-3636.
20. Schwertz H, Koster S, Kahr WH, et al. Anucleate platelets generate progeny[J]. Blood, 2010, (115):3801-3809.
21. Li J, van der Wal DE, Zhu L, et al. Fc-independent phagocytosis:implications for IVIG and other therapies in immune-mediated thrombocytopenia[J]. Cardiovasc Hematol Disord Drug Targets, 2013, (13):50-58.
22. Xu X, Wu J, Zhai Z, et al. A novel fibrinogen Bbeta chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia[J]. Thromb Haemost, 2006, (95):931-935.
23. Rand ML, Wang H, Bang KW, et al. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence[J]. J Thromb Haemost, 2004, (2):651-659.
24. Webster ML, Zhu G, Li Y, et al. Fc-independent phagocytosis:implications for intravenous IgG therapy in immune thrombocytopenia[J]. Cardiovasc Hematol Disord Drug Targets, 2008, (8):278-282.
25. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun, 2015, (6):7737-7753.
26. van Der Wal D, Zhu G, Li J, et al. Desialylation: A Novel Platelet Clearance Mechanism and a Potential New Therapeutic Target in Anti-GPIb Antibody Mediated Thrombocytopenia [J]. 54th ASH Annual Meeting, 2012, (Session: 311. Disorders of Platelet Number or Function: Biology of antibody mediated platelet destruction:HIT, NAIT and mechanisms of ivig).
27. Sorensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptorexpressing liver macrophages and hepatocytes[J]. Blood, 2009, (114):1645-1654.
28. Rumjantseva V, Hoffmeister KM. Novel and unexpected clearance mechanisms for cold platelets[J]. Transfus Apher Sci, 2010, (42):63-70.
29. Jansen AJ, Josefsson EC, Rumjantseva V, et al . Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice[J]. Blood, 2012, (119):1263-1273.
30. Jansen AJ, Peng J, Zhao HG, et al. Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia[J]. Am J Hematol, 2015, (90):E94-95.
31. Wang Y, Reheman A, Spring CM, et al. Plasma fibronectin supports hemostasis and regulates thrombosis[J]. J Clin Invest, 2014, (124):4281-4293.
32. Yougbare I, Lang S, Yang H, et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage[J]. J Clin Invest, 2015, (125):1545-1556.
33. Vadasz B, Chen P, Yougbare I, et al. Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia[ J]. Gene and Diseases, 2015, (2):173-185.
34. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation[J]. Semin Thromb Hemost, 2006, (32 Suppl 1):32-38.
35. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation[J]. Arterioscler Thromb Vasc Biol, 2002, (22):1381-1389.
36. Dopheide SM, Maxwell MJ, Jackson SP. Shear-dependent tether formation during platelet translocation on von Willebrand factor[J]. Blood, 2002, (99):159-167.
37. Goto S, Salomon DR, Ikeda Y, et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets[J]. J Biol Chem, 1995, (270):23352-23361.
38. Ruggeri ZM. Mechanisms initiating platelet thrombus formation[J]. Thromb Haemost, 1997, (78):611-616.
39. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen[J]. J Clin Invest, 2000, (106):385-392.
40. Andre P, Denis CV, Ware J, et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins[J]. Blood, 2000, (96):3322-3328.
41. Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis[J]. Thromb Haemost, 2014, (111):279-289.
42. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow[J]. Cell, 1998, (94):657-666.
43. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen[J]. EMBO J, 2001, (20):2120-2130.
44. Wilkins JA, Li A, Ni H, et al. Control of beta1 integrin function. Localization of stimulatory epitopes[J]. J Biol Chem, 1996, (271):3046-3051.
45. Ni H, Li A, Simonsen N, et al. Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain[J]. J Biol Chem, 1998, (273):7981-7987.
46. Ni H, Wilkins JA. Localisation of a novel adhesion blocking epitope on the human beta 1 integrin chain[J]. Cell Adhes Commun, 1998, (5):257-271.
47. Bledzka K, Smyth SS, Plow EF. Integrin alphaIIbbeta3:from discovery to efficacious therapeutic target[J]. Circ Res, 2013, (112):1189-1200.
48. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis[J]. Proc Natl Acad Sci U S A, 1998, (95):9524-9529.
49. Bergmeier W, Piffath CL, Goerge T, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis[J]. Proc Natl Acad Sci U S A, 2006, (103):16900-16905.
50. Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice[J]. J Exp Med, 2001, (193):459-469.
51. Nuyttens BP, Thijs T, Deckmyn H, et al. Platelet adhesion to collagen[J]. Thromb Res, 2011, (127):S26-29.
52. Bergmeier W, Hynes RO. Extracellular matrix proteins in hemostasis and thrombosis[J]. Cold Spring Harb Perspect Biol, 2012, (4).
53. Berndt MC, Metharom P, Andrews RK. Primary haemostasis:newer insights[J]. Haemophilia, 2014, (20):15-22.
54. Gui T, Reheman A, Ni H, et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV[J]. J Thromb Haemost, 2009, (7):1843-1851.
55. Gui T, Reheman A, Funkhouser WK, et al. In vivo response to vascular injury in the absence of factor IX:examination in factor IX knockout mice[J]. Thromb Res, 2007, (121):225-234.
56. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis[J]. Nature, 2001, (413):74-78.
57. Celikel R, McClintock RA, Roberts JR, et al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha[J]. Science, 2003, (301):218-221.
58. Ni H, Ramakrishnan V, Ruggeri ZM, et al. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V[J]. Blood, 2001, (98):368-373.
59. Li C, Piran S, Chen P, et al. The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies[J]. J Clin Invest, 2011, (121):4537-4547.
60. Reheman A, Tasneem S, Ni H, et al. Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1[J]. Thromb Res, 2010, (125):e177-183.
61. Yang H, Reheman A, Chen P, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo[J]. J Thromb Haemost, 2006, (4):2230-2237.
62. Yang H, Lang S, Zhai Z, et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface Pselectin expression[J]. Blood, 2009, (114):425-436.
63. Ni H. Unveiling the new face of fibronectin in thrombosis and hemostasis[J]. J Thromb Haemost, 2006, (4):940-942.
64. Wang Y, Ni H. Fibronectin: extra domain brings extra risk?[J]. Blood, 2015, (125):3043-3054.
65. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation[J]. J Thromb Haemost, 2005, (3):875-883.
66. Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal trans duction[J]. Hematol Oncol Clin North Am, 2013, (27):585-611.
67. Johnston-Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor-mediated platelet aggregation[J]. J Cell Physiol, 2011, (226):46-51.
68. Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets[J]. J Thromb Haemost, 2009; (7 Suppl 1):187-190.
69. Varga-Szabo D, Braun A, Nieswandt B. STIM and Orai in platelet function[J]. Cell Calcium, 2011, (50):270-278.
70. Jin J, Quinton TM, Zhang J, et al. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors[J]. Blood, 2002, (99):193-198.
71. Arthur JF, Gardiner EE, Kenny D, et al. Platelet receptor redox regulation[J]. Platelets, 2008, (19):1-8.
72. Carrim N, Walsh TG, Consonni A, et al. Role of focal adhesion tyrosine kinases in GPVI-dependent platelet activation and reactive oxygen species formation[J]. PLoS One, 2014, (9):e113679.
73. Walsh TG, Berndt MC, Carrim N, et al. The role of Nox1 and Nox2 in GPVI-dependent platelet activation and thrombus formation[J]. Redox Biol, 2014, (13):178-186.
74. Chen W, Thielmann I, Gupta S, et al. Orai1-induced storeoperated Ca(2+) entry enhances phospholipase activity and modulates canonical transient receptor potential channel 6 function in murine platelets[J]. J Thromb Haemost, 2014, (12):528-539.
75. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Wille brand factor[J]. Blood, 2009, (113):1809-1817.
76. Dunne E, Spring CM, Reheman A, et al. Cadherin 6 has a functional role in platelet aggregation and thrombus for mation[J]. Arterioscler Thromb Vasc Biol, 2012, (32):1724-1731.
77. Ni H, Papalia JM, Degen JL, et al. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain[J]. Blood, 2003, (102):3609-3614.
78. Zhai Z, Wu J, Xu X, et al. Fibrinogen controls human platelet fibronectin internalization and cell-surface retention[J]. J Thromb Haemost, 2007, (5):1740-1746.
79. Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured art erioles[J]. Proc Natl Acad Sci U S A, 2003, (100):2415-2419.
80. Smith SA, Travers RJ, Morrissey JH. How it all starts:Initiation of the clotting cascade[J]. Crit Rev Biochem Mol Biol, 2015, (50):1-11.
81. Mammadova-Bach E, Ollivier V, Loyau S, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation[J]. Blood, 2015, (126):683-691.
82. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology[J]. Vascul Pharmacol, 2014, (62):72-81.
83. Dumas JJ, Kumar R, Seehra J, et al. Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation[J]. Science, 2003, (301):222-226.
84. Lechtenberg BC, Freund SM, Huntington JA. GpIbalpha interacts exclusively with exosite II of thrombin[J]. J Mol Biol, 2014, (426):881-893.
85. Wang Y, Carrim N, Ni H. Fibronectin orchestrates thrombosis and hemostasis[J]. Oncotarget Journal, 2015; (6):19350-19351.
86. Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders[J]. Haemophilia, 2012, (18):154-160.
87. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study[J]. J Thromb Haemost, 2014, (12):497-504.
88. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies[J]. Blood, 2006, (108):943-946.
89. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by antiplatelet GPIIbIIIa versus GPIbalpha antibodies[J]. Am J Hematol, 2012, (87):206-208.
90. Semple JW, Italiano JE, Jr., Freedman J. Platelets and the immune continuum[J]. Nat Rev Immunol, 2011, (11):264-274.
91. Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy[J]. Blood, 2010, (116):3660-3668.
92. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: re sponse to intravenous IgG therapy[J]. Blood, 2006, (107):2976-2983.
93. Sachs UJ. Fetal/neonatal alloimmune thrombocytopenia[J]. Thromb Res, 2013;(131 Suppl 1):S42-46.
94. Liang Y, Qiu H, Glinka Y, et al. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcgammaRIIb[J]. J Gene Med, 2011, (13):470-477.
95. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia:induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model[J]. Transfusion, 2012, (52):1446-1457.
96. Tiller H, Killie MK, Husebekk A, et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys[J]. Acta Obstet Gynecol Scand, 2012, (91):79-86.
97. Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis[J]. Nat Med, 2013, (19):586-594.
98. Lindemann S, Kramer B, Seizer P, et al. Platelets, inflammation and atherosclerosis[J]. J Thromb Haemost, 2007;(5 Suppl 1):203-211.
99. Yang Y, Andrews MC, Hu Y, et al. Anthocyanin extract from black rice significantly ameliorates platelet hyperactivity and hypertriglyceridemia in dyslipidemic rats induced by high fat diets[J]. J Agric Food Chem, 2011, (59):6759-6764.
100. Yang Y, Shi Z, Reheman A, et al. Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases[J]. PLoS One, 2012, (7):e37323.
101. Song F, Zhu Y, Shi Z, et al. Plant food anthocyanins inhibit platelet granule secretion in hypercholestero laemia: Involving the signalling pathway of PI3KAkt[ J]. Thromb Haemost, 2014, (112):981-991.
102. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype[J]. Nat Med, 2007, (13):1086-1095.
103. Ni H. The platelet "sugar high" in diabetes[J]. Blood, 2012, (119):5949-5951.
104. Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36[J]. Blood, 2012; (119):6136-6144.
105. Weyrich AS, Schwertz H, Kraiss LW, et al. Protein synthesis by platelets: historical and new perspectives[J]. J Thromb Haemost, 2009, (7):241-246.
106. Xu X, Carrim N, Lavalle C, et al. Platelets Are Versatile Cells: Emerging new roles in inflammation, immune response, angiogenesis, and atherosclerosis[J]. Critical Reviews in Clinical Laboratory Sciences, In press.
107. Li C, Li J, Li Y, et al. Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries[J]. Adv Hematol, 2012, (2012):384685-384699.
108. NordingHM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis[J]. Front Immunol, 2015, (6):98-109.
109. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling[J]. Blood, 2010, (116):661-670.